Page 5 - Pfizer

Pfizer India Q2 PAT rises to Rs 226 crore on lower costs, price hikes

Its cost of materials consumed fell 2.1% to Rs 94.4 crore, accounting for about 21% of total expenses in the quarter

Pfizer's Paxlovid antiviral lowered long-Covid risk, suggests study

The research, based on an analysis of electronic health records in databases maintained by the Department of Veterans Affairs, suggests that wider use of Paxlovid won't just stave off critical disease

Pfizer, BioNTech start Covid-flu combination vaccine early-stage study

The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored Covid-19 booster shot

Covid vaccine to cost $110-$130 per dose after US govt stops buying: Pfizer

Pfizer will charge USD 110 to USD 130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses. A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots. The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to

Pfizer's Covid vaccine price hike seen giving revenue boost for yrs: Report

Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set

Zoom to Moderna: The extraordinary rise and fall of Covid billionaires

Their rise and subsequent slump were sharper than the other 131 members of the Bloomberg Billionaires Index whose net worth more than doubled, but wasn't as reliant on how Covid altered lives

US FDA authorises updated Moderna, Pfizer Covid boosters for children

The US Food and Drug Administration (FDA) has authorised the updated Moderna and Pfizer-BioNTech Covid-19 booster shots for children as young as five

Mehul Kothari recommends Buy on CAMS, Pfizer; Check Why

According to the technical analyst from Anand Rathi, CAMS can rally to Rs 2,700, while Pfizer can be bought for a target of Rs 4,700.

European Medicines Agency clears Pfizer-BioNTech's tweaked Covid booster

The European Medicines Agency has recommended the authorisation of a tweaked booster dose of the Pfizer-BioNTech coronavirus vaccine that includes protection against two of the latest versions of omicron, as countries look to bolster their immunisation programs ahead of winter. The EU regulator said Monday that laboratory studies suggest the combination vaccine which targets both the original COVID-19 virus as well as the omicron subvariants BA.4 and BA.5 should trigger an effective immune response. The vaccine is expected to be as safe as the original version, but the agency will continue to track its rollout globally since the data is limited. The U.S. Food and Drug Administration gave the modified vaccine shot the green light last month. According to the World Health Organisation, the BA.5 version of omicron is responsible for most of the COVID-19 spreading globally; it made up about 87% of all virus sequences shared with the biggest public database. Earlier this month, the .

Canada approves Pfizer Covid-19 vaccine for kids under five years

Health Canada has approved Pfizer's Covid-19 vaccine to immunise children under the age of five

Moderna sues Pfizer, BioNTech over patents behind Covid-19 vaccine

COVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna's technology in order to make their own vaccine. Moderna said on Friday that Pfizer and BioNTech's vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax. The company filed patent infringement lawsuits in both US federal court and a German court. A Pfizer spokeswoman declined to comment, saying the company had not been served with a copy of the litigation. Moderna and Pfizer's two-shot vaccines both use mRNA technology to help patients fight the coronavirus. The mRNA vaccines work by injecting a genetic code for the spike protein that coats the surface of the coronavirus. That code, the mRNA, is encased in a little ball of fat, and instructs the body's cells to make some harmless spike copies that train the immune system to recognise the real virus. Moderna CEO Stephane Ban

Pfizer's Covid-19 vaccine shows 73% efficacy in children under 5 years

The Pfizer-BioNTech Covid-19 vaccine was 73 per cent effective in protecting children ages 6 months through 4 years during the time when the Omicron strain was highly prevalent, Pfizer has announced

Pfizer's Covid vaccine 73.2% effective in kids under 5, shows new data

The updated data showed 13 children had Covid, at least seven days after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine, compared with 21 cases among those who received a placebo

Pfizer CEO Albert Bourla tests positive for Covid, with mild symptoms

Albert Bourla said Monday that he started taking Pfizer's Paxlovid pill treatment and is isolating while he recovers

Pfizer's managing director S Sridhar to take an early retirement

Over the past 14 years, Sridhar has led a number of key leadership positions in Pfizer, including serving as the Chief Financial Officer for a period of eight years

EU regulator begins review of Pfizer-BioNTech's variant-adapted Covid shot

The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4-bn deal

Pfizer has been on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade

Pfizer buying spree continues with $5.4 billion hematology deal

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus

Pfizer India Q1 profit falls 83% to Rs 33 crore, revenue down 21%

The drug firm said exceptional items for June quarter comprised Rs 130 crore on account of a voluntary retirement scheme and Rs 6 crore for restructuring to drive business transformation.

Stocks to Watch: Britannia, GAIL, Reliance, Adani Enterprises, Paytm, Nykaa

Stocks to Watch: With oil prices staging a dramatic reversal, related stocks, along with rate-sensitive sectors will be on the radar as RBI announces its monetary policy outcome Friday.